Amarin Appoints Medpace as CRO for two Phase 3 Cardiovascular Trials

News   Oct 20, 2009

 
Amarin Appoints Medpace as CRO for two Phase 3 Cardiovascular Trials
 
 
 

RELATED ARTICLES

Apple Allergens as an Effective Option for Treating Apple Allergy

News

Researchers have now proven in a Phase II trial that the apple allergen "Mal d 1" significantly reduces the symptoms of apple allergy and is therefore an effective and safe treatment option.

READ MORE

Blockchain & AI for Biomedical Applications

News

Biogerontology Research Foundation Chief Science Officer (CSO) co-authored the landmark paper in the journal Oncotarget on the convergence of blockchain and AI to decentralize and galvanize healthcare and biomedical research.

READ MORE

Source of a Potent Greenhouse Gas Identified

News

A study of a Lake Erie wetland suggests that scientists have vastly underestimated the number of places methane-producing microbes can survive—and, as a result, today’s global climate models may be misjudging the amount of methane being released into the atmosphere.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE